Zai Lab
Junli Zhang has a diverse work experience in the field of biostatistics and data analysis. They have recently worked as a Principal Biostatistician at Zai Lab since April 2021. Prior to that, they held positions at dMed Biopharmaceutical Co., Ltd. as a Senior Biostatistician from July 2018 to April 2021 and as a Biostatistician II from September 2017 to June 2018. Before joining dMed, they worked at PPD as a Biostatistician from April 2017 to July 2017 and as an Associate Biostatistician from November 2015 to March 2017. Junli Zhang also has experience in data analysis at Catalina Marketing, where they worked as an Analyst in 2015 and 2014. Their responsibilities included conducting quantitative analyses, applying statistical methods, and deriving insights from consumer purchase data. Prior to their career in biostatistics, Junli Zhang had internships at HSBC Bank China in 2013 and Bank of Shanghai in 2012, where they gained experience in HR and sales data management respectively.
Junli Zhang earned a Master's degree in Statistics from Rutgers University in 2013-2015. Prior to that, they obtained a Bachelor's degree in Insurance from East China Normal University in 2009-2013. They also participated as an exchange student at Purdue University in 2011-2012, focusing on management. In 2015, Junli Zhang received a certification as a SAS Certified Base Programmer for SAS 9 from SAS Institute.
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.